Canopy Growth stock analysis
Canopy Growth (CGC) Stock Price & Analysis
CGC Stock Chart & Stats
- Day’s Range
- $0.43 - $0.47
- 52-Week Range
- $0.43 - $2.38
- Previous Close
- $0.47
- Volume
- N/A
- Average Volume (3M)
- 2.85M
- Market Cap
- $216.18M
- Enterprise Value
- $494.26M
- Total Cash (Recent Filing)
- $319.79M
- Total Debt (Recent Filing)
- $281.44M
- Price to Earnings (P/E)
- ―
- Beta
- 1.58
- Next Earnings
- Feb 05, 2027 (Est.)
- EPS Estimate
- -0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Broad Revenue Growth
Broad-based revenue growth indicates improving demand across Canopy’s portfolio and markets rather than reliance on a single product. Continued expansion in cannabis, medical, adult-use, and international channels can strengthen operating scale and support improved earnings power over the next several quarters.
International Market Expansion
Rapid international growth, supported by stronger flower availability and route-to-market access, expands Canopy’s addressable patient base beyond Canada. European certifications, product expansion, and new market entry can create a more diversified and durable revenue platform.
Liquidity And Operating Efficiency
A substantial liquidity position gives Canopy runway to fund operations and execute strategic initiatives while management pursues cost savings. Planned MTL synergies could lower the recurring expense base, improve efficiency, and provide additional support for the path toward positive adjusted EBITDA.
Bears Say
Deep Operating Losses
Very negative operating and net margins show that the core business has not yet achieved an economically sustainable cost structure. Even with improvement from prior distress, persistent losses can consume equity, limit reinvestment capacity, and delay internally funded growth.
Persistent Cash Burn
Negative operating and free cash flow mean Canopy is not currently funding its business internally. Continued cash consumption increases dependence on its liquidity and potential financing actions, while reducing flexibility to invest in products, market expansion, or operational improvements.
High Cultivation Costs
A structurally higher cultivation cost base can constrain gross margins and make Canopy less competitive when cannabis pricing is pressured. The focus on higher-quality flower may support differentiation, but it also requires successful yield and utilization improvements to close the cost gap.
Canopy Growth News
CGC FAQ
What was Canopy Growth’s price range in the past 12 months?
What is Canopy Growth’s market cap?
When is Canopy Growth’s upcoming earnings report date?
How were Canopy Growth’s earnings last quarter?
Is Canopy Growth overvalued?
Does Canopy Growth pay dividends?
What is Canopy Growth’s EPS estimate?
How many shares outstanding does Canopy Growth have?
What happened to Canopy Growth’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Canopy Growth?
What is the TipRanks Smart Score and how is it calculated?
Canopy Growth Stock Smart Score
Company Description
Canopy Growth
Canopy Growth Corporation, through its various operating units, is actively involved in the cultivation, marketing, and distribution of cannabis and hemp-derived products. These offerings serve both recreational consumers and medical patients across key markets including Canada, the United States, and Germany. The company's business activities are structured into two main divisions: its global cannabis operations and its diverse portfolio of other consumer goods. Its extensive product line features dried cannabis flower, a variety of extracts and concentrates, beverages, edible gummies, and vaporization products. Canopy Growth commercializes these goods under numerous well-known brands such as Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra. Formed in 2009, the enterprise initially operated as Tweed Marijuana Inc. before adopting its current name, Canopy Growth Corporation, in September 2015. Its principal office is located in Smiths Falls, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Luc Mongeau
- Employees
- 1,128
- Website
- www.canopygrowth.com
- Address
- 1 Hershey Drive, Smiths Falls, ON, K7A 0A8, CA
Canopy Growth (CGC) Earnings & Revenues
CGC Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Canopy reported strong consolidated, cannabis, international, medical, and adult-use revenue growth; improved operating efficiency; a narrower adjusted EBITDA loss; substantial liquidity; and progress in cultivation, EU GMP certification, and international expansion. The main negative factors were the 44% decline in Storz & Bickel revenue, lower consolidated gross margin due primarily to the Veteran Affairs Canada reimbursement-rate reduction, ongoing negative adjusted EBITDA, and the company's acknowledgment that cultivation costs are not yet best in class. Management nevertheless expressed confidence in achieving positive adjusted EBITDA in the second half of fiscal 2027 and in realizing further benefits from cultivation and operating initiatives.
View all CGC earnings summariesCGC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 0 | 16 |
| Technical Analysis | 6 | 0 | 4 |
| Moving Averages | 0 | 0 | 12 |













